Needham & Company LLC reiterated their buy rating on shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) in a report issued on Thursday morning. The brokerage currently has a $25.00 target price on the stock.

“Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY.”,” the firm’s analyst wrote.

Several other research analysts have also recently commented on the company. BidaskClub cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, July 28th. Zacks Investment Research cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 10th. ValuEngine cut Aquinox Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 15th. Cantor Fitzgerald reissued a buy rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Thursday. Finally, Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $22.50.

Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at $10.88 on Thursday. Aquinox Pharmaceuticals has a 52-week low of $10.68 and a 52-week high of $19.97.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/11/12/aquinox-pharmaceuticals-inc-aqxp-given-buy-rating-at-needham-company-llc.html.

A number of large investors have recently added to or reduced their stakes in AQXP. Geode Capital Management LLC raised its stake in Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the period. Alps Advisors Inc. raised its stake in Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the period. Bank of New York Mellon Corp raised its stake in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the period. Archon Partners LLC raised its stake in Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in Aquinox Pharmaceuticals in the second quarter valued at approximately $874,000. Hedge funds and other institutional investors own 95.15% of the company’s stock.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.